In this issue:
Infliximab or adalimumab for Behçet's syndrome
Tocilizumab for giant cell arteritis
Biologics for TMJ inflammation in JIA
Multi-DMARD failure in PSA
Canakinumab in familial Mediterranean fever
Risk of malignancy related to ixekizumab
Flare prediction after TNF inhibitor tapering in axial spondylarthritis
Rituximab retention rate in systemic sclerosis
Preferences for tapering biologic DMARDs
FDG-PET monitoring of giant cell arteritis
Please login below to download this issue (PDF)